SYN-AKE

Syn-ake (Tripeptide-3; dipeptide diaminobutyroyl benzylamide diacetate) is a synthetic tripeptide designed to mimic the mechanism of waglerin-1, a neurotoxic peptide component of Wagler's pit viper (Tropidolaemus wagleri) venom, and formulated as a cosmetic active ingredient claimed to reduce dynamic wrinkle formation by antagonizing muscle nicotinic acetylcholine receptors (nAChR) at facial expression muscle neuromuscular junctions, analogous to a topically applied reversible botulinum toxin mimic. The proposed mechanism involves competitive antagonism at the muscle-type nAChR, theoretically reducing motor signal transmission to facial expression muscles and attenuating the contraction-driven wrinkle formation that produces dynamic lines; this mechanism is pharmacologically plausible at the molecular level given the established nAChR antagonism of waglerin-1, but has not been validated by independent in vivo human or animal studies in the indexed scientific literature. No published peer-reviewed in vivo human studies, controlled animal efficacy studies, or pharmacokinetic data for syn-ake are indexed in PubMed; available indexed literature is limited to a single in silico and in vitro study that does not constitute clinical or preclinical in vivo evidence. Syn-ake has no FDA approval and no regulatory drug status in any jurisdiction; it is a cosmetic ingredient marketed on the basis of its theoretical mechanism and supplier-conducted unpublished testing, and no independently published peer-reviewed clinical evidence supports its claimed anti-wrinkle efficacy as a topically applied formulation.